Stocks and Investing
Stocks and Investing
Thu, March 30, 2017
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Martin Auster Initiated (BMRN) at Hold and Held Target at $92 on, Mar 30th, 2017
Martin Auster of UBS, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Hold and Held Target at $92 on, Mar 30th, 2017.
Martin has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Martin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Martin
- Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $110 on, Tuesday, February 7th, 2017
- Kennen MacKay of "Credit Suisse" Initiated at Buy with Decreased Target to $107 on, Monday, January 23rd, 2017
Contributing Sources